MIR-133A IS A PREDICTIVE BIOMARKER IN PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED CHEMOTHERAPY

被引：0
|
作者：
Ng, Simon S.
Dong, Yujuan
Leung, Wing Wa
Ma, Brigette B.
To, Ka Fai
Sung, Joseph J.
Yu, Jun
机构：
来源：
GASTROENTEROLOGY | 2018年 / 154卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
374
引用
收藏
页码：S88 / S88
页数：1
相关论文
共 50 条
  • [1] Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Beatty, Gregory L.
    Giantonio, Bruce J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) : 683 - 688
  • [2] Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)
    Berretta, Massimiliano
    Zanet, Ernesto
    Nasti, Guglielmo
    Lleshi, Arben
    Frustaci, Sergio
    Fiorica, Francesco
    Bearz, Alessandra
    Talamini, Renato
    Lestuzzi, Chiara
    Lazzarini, Renzo
    Fisichella, Rossella
    Cannizzaro, Renato
    Iaffaioli, Rosario Vincenzo
    Berretta, Salvatore
    Tirelli, Umberto
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2012, 55 (02) : 271 - 275
  • [3] PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
    Papadaki, C.
    Saridaki, Z.
    Tzardi, M.
    Sfakianaki, M.
    Sfakiotaki, G.
    Trypaki, M.
    Messaritakis, I.
    Mavroudis, D.
    Georgoulias, V.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] Oxaliplatin-based Chemotherapy in Patients Aged 75 Years or Older with Metastatic Colorectal Cancer
    Fukuchi, Minoru
    Ishibashi, Keiichiro
    Tajima, Yusuke
    Okada, Norimichi
    Yokoyama, Masaru
    Chika, Noriyasu
    Hatano, Satoshi
    Matsuzawa, Takeaki
    Kumamoto, Kensuke
    Kumagai, Youichi
    Baba, Hiroyuki
    Mochiki, Erito
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2013, 33 (10) : 4627 - 4630
  • [5] Oxaliplatin-based chemotherapy in the management of colorectal cancer
    Capdevila, Jaume
    Elez, Elena
    Peralta, Sergio
    Macarulla, Teresa
    Javier Ramos, Francisco
    Tabernero, Josep
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (08) : 1223 - 1236
  • [6] Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer
    Rubbia-Brandt, L
    Audard, V
    Sartoretti, P
    Roth, AD
    Brezault, C
    Le Charpentier, M
    Dousset, B
    Morel, P
    Soubrane, O
    Chaussade, S
    Mentha, G
    Terris, B
    ANNALS OF ONCOLOGY, 2004, 15 (03) : 460 - 466
  • [7] Evaluation of the CpG island methylator phenotype as a predictive biomarker for adjuvant oxaliplatin-based chemotherapy in colorectal cancer.
    Shiovitz, Stacey
    Wu, Chen
    Yu, Ming
    Gourgioti, Georgia
    Raptou, Georgia
    Kotoula, Vassiliki
    Pentheroudakis, George E.
    Kalogeras, Konstantine T.
    Fountzilas, George
    Grady, William M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [8] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Hesketh, P. J.
    Sanz-Altamira, P.
    Bushey, J.
    Malek, K.
    Insalaco, L.
    Hesketh, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Hesketh, Paul J.
    Sanz-Altamira, Pedro
    Bushey, Julie
    Hesketh, Ann M.
    SUPPORTIVE CARE IN CANCER, 2012, 20 (05) : 1043 - 1047
  • [10] Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    Paul J. Hesketh
    Pedro Sanz-Altamira
    Julie Bushey
    Ann M. Hesketh
    Supportive Care in Cancer, 2012, 20 : 1043 - 1047
12345